Recent Revenue Surge: KalVista Pharmaceuticals has been a hot topic on X recently, with discussions focusing on the company’s strong third-quarter revenue of $13.7 million, far exceeding expectations. Many users are impressed by the rapid growth in prescribers and patient start forms for their key product, signaling strong market adoption. The successful launch in Germany has also sparked excitement about global expansion.
Pipeline Potential: Conversations on X also highlight optimism around KalVista’s drug pipeline, particularly KVD933 for hereditary angioedema, with some calling it a game-changer. However, there are concerns about the company’s cash burn rate, with a few voicing caution over long-term sustainability. The mix of hope and skepticism keeps the dialogue lively and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
KalVista Pharmaceuticals Insider Trading Activity
KalVista Pharmaceuticals insiders have traded $KALV stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $KALV stock by insiders over the last 6 months:
- BENJAMIN L PALLEIKO (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 8 sales selling 81,525 shares for an estimated $1,190,066.
- CHRISTOPHER YEA (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 6 sales selling 44,229 shares for an estimated $664,189.
- PAUL K. AUDHYA (CHIEF MEDICAL OFFICER) has made 0 purchases and 5 sales selling 16,588 shares for an estimated $224,768.
- BRIAN PIEKOS (Chief Financial Officer) sold 4,471 shares for an estimated $60,139
- NICOLE SWEENY (Chief Commercial Officer) has made 0 purchases and 2 sales selling 3,344 shares for an estimated $44,508.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KalVista Pharmaceuticals Hedge Fund Activity
We have seen 80 institutional investors add shares of KalVista Pharmaceuticals stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 3,925,000 shares (-84.0%) from their portfolio in Q3 2025, for an estimated $47,806,500
- MILLENNIUM MANAGEMENT LLC added 1,755,594 shares (+515.4%) to their portfolio in Q3 2025, for an estimated $21,383,134
- GOLDMAN SACHS GROUP INC added 1,665,783 shares (+1239.4%) to their portfolio in Q3 2025, for an estimated $20,289,236
- PARKMAN HEALTHCARE PARTNERS LLC added 1,055,940 shares (+155.5%) to their portfolio in Q3 2025, for an estimated $12,861,349
- AMERIPRISE FINANCIAL INC removed 909,676 shares (-96.2%) from their portfolio in Q3 2025, for an estimated $11,079,853
- FREESTONE GROVE PARTNERS LP added 704,448 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,580,176
- SIO CAPITAL MANAGEMENT, LLC added 683,819 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,328,915
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KalVista Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $KALV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/11/2025
To track analyst ratings and price targets for KalVista Pharmaceuticals, check out Quiver Quantitative's $KALV forecast page.
KalVista Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $KALV recently. We have seen 5 analysts offer price targets for $KALV in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $28.0 on 11/11/2025
- Jonathan Wolleben from JMP Securities set a target price of $28.0 on 09/12/2025
- Serge Belanger from Needham set a target price of $28.0 on 09/12/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $27.0 on 07/11/2025
- Joseph Schwartz from Leerink Partners set a target price of $20.0 on 07/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
